Sanofi-aventis calls for an effective policy against drug counterfeiting

Sanofi-aventis calls for an effective policy
against drug counterfeiting
Paris, May 15, 2007 - The first European parliamentary symposium on drug counterfeiting took
place yesterday in Brussels, under the joint chairmanship of French and British members of the
European Parliament, Françoise GROSSETETE and John BOWIS, members of the European
Parliament Commission on Environment, Public Health and Food Safety.
Jean-François DEHECQ, Chairman of sanofi-aventis, opened the discussion. Günter
VERHEUGEN, European Commissioner responsible for Enterprise and Industry policy, brought
the proceedings to a close.
The themes for discussion were the following:
- European and international measures against drug counterfeiting
- latest initiatives taken by the industry to prevent counterfeiting by securing supply chain
of pharmaceuticals
- and new technological systems.
Jean-François DEHECQ made on the following points:
- Drug counterfe iting is a public health menace, proliferating at vast speed with dozens
of new instances appearing every day in all parts of the globe
- All pharmaceutical companies are concerned, producers of innovative drugs or
generics alike
- Drug counterfeiters must be prosecuted as such since their products can have dramatic
consequences on patients lives
- In Europe, parallel trade circuits are among the major vectors used by counterfeiters
to sell their fake products
- The problem has to be solved on a global level, but Europe has an essential leading
role to play since it can, and must, be the driver of any action.
"For too long, we have underestimated the drug counterfeiting situation. It used to be marginal,
it is now totally industrialized ", said Jean-François DEHECQ.
"Medicines are not an ordinary product. Before they are marketed, drugs must be granted
official approval, (MA - Marketing Authorization). The MA is a guarantee of safety, quality and
efficacy of products. "Fake medicines" do not respect these requirements and are therefore a
health hazard", he added.
Speaking on Europe's role in this effort, Jean-François DEHECQ listed the three lines of action
for an effective strategy in the fight against counterfeiters.
1) First, counterfeit medicines have to be prevented from entering European markets and supply
- by reassessing the problem of parallel trade channels and establishing better control
of distribution channels
- by considering the « solution » of a ban on medicines re-packaging, unless the rules
imposed upon the manufacturer of the original drug are strictly complied with.
2) Furthermore, an entire legal armamentarium has to be set up against counterfeiters.
3) And finally, there has to be a wholehearted commitment to implement international health
"Although counterfeiting is a global problem which must be fought worldwide, there is an
essential need for Europe to play a driving role in the fight against drug counterfeiting",
Jean-François DEHECQ concluded.
About sanofi-aventis
Sanofi-aventis is one of the world leaders in the pharmaceutical industry, ranking number one in
Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading
positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic
diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Informasjonen er sendt gjennom Cision

Om oss

Et stort farmasøytisk selskap som setter fokus på helse over hele verden. Med en nettoomsetning i 2004 på 26 750 millioner euro, og mer enn 100 000 ansatte i rundt 100 land er Sanofi-aventis er et av verdens ledende legemiddel selskap og er blant topp 6 i Norge. Det globale hovedkontoret er i Paris, Frankrike. Det norske hovedkontoret befinner seg på Lysaker. 7 viktige behandlingsområder Sanofi-aventis fokuserer sine aktiviteter på 7 viktige behandlingsområder: Hjerte-karsykdommer (f. eks. Hypertensjon)Thrombose (Blodpropp)Onkologi (Kreft)Sykdommer i sentralnervesystemet (f.eks. MS) DiabetesOsteoporose (Benskjørhet) Gode legemidler for millioner av pasienter Sanofi-aventis’ portefølje av markedsførte produkter inkluderer flere legemidler som er verdensledere i sine respektive klasser, innen områdene blodpropp, hjerte-karsykdommer, søvnforstyrrelser, epilepsi, diabetes og kreft. Svært produktiv og nyskapende forskning og utvikling Grunnlaget for sanofi-aventis' verdensomspennende fremgang er en svært produktiv og nyskapende forsknings- og produktutviklingsorganisasjon med rundt 11 000 forskere som jobber i mer enn 20 forskningssentere på tre kontinenter. Her legger vi vekt på å forske frem nyskapende terapeutiske behandlinger. For øyeblikket er rundt tretti forsknings- og produktutviklingsprosjekter kommet meget langt i utviklingen. Se forøvrig hjemmesiden til Legemiddelindustriforeningen. For mer informasjon om sanofi-aventis rundt om i verden kan du besøke